The rise of Sildenafil initially sparked a boom for pharma, nevertheless recent developments present a complicated picture for shareholders. Off-patent versions are eating into profits, and continued legal battles add additional difficulty to the landscape. While certain companies might still benefit from related offerings, the general trajectory s